New breast cancer drug trial aims to shrink tumors before surgery
NCT ID NCT07196774
Summary
This study is testing whether a new drug called SHR-A1811 works better than the current standard treatment for shrinking HER2-positive breast tumors before surgery. About 740 women with early or locally advanced breast cancer will receive either the new drug or standard chemotherapy plus targeted therapy. The main goal is to see which treatment leads to more patients having no cancer cells left in their breast and lymph nodes after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shengjing Hospital, China Medical University
RECRUITINGShenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.